FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of February, 2004
Commission File Number 001-13896
Elan Corporation, plc
(Translation of registrant's name into English)
Lincoln House, Lincoln Place, Dublin 2, Ireland
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
Form 20-F /X/ Form 40-F / /
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1):
Yes / / No /X/
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of
a Form 6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7):
Yes / / No /X/
-2-
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of
a Form 6-K if submitted to furnish a report or other document that the
registrant foreign private issuer must furnish and make public under the laws of
the jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant's "home country"), or under the rules of the home
country exchange on which the registrant's securities are traded, as long as the
report or other document is not a press release, is not required to be and has
not been distributed to the registrant's security holders, and, if discussing a
material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in
this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes / / No /X/
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b):
This Report of Foreign Issuer on Form 6-K is incorporated by reference into the
Post-Effective Amendments on Forms F-3 and S-8 to Form F-4 Registration
Statement of Elan Corporation, plc (Registration No. 333-12756), the
Registration Statement on Form F-3 of Elan Corporation, plc and Athena
Neuroscience Finance, LLC (Registration No. 333-13130), and the Registration
Statements on Form S-8 of Elan Corporation, plc (Registration Nos. 333-13996,
333-12344, 333-11940, 333-09644, 333-09284, 333-09048, 333-08384, 333-07361,
333-07136, 333-14240, 33-27506, 333-100252 and 333-100556).
EXHIBIT LIST
Exhibit Description
99.1 Press release dated February 16, 2004 titled:
Executive vice president Seamus Mulligan leaving Elan upon
successful completion of recovery plan - Elan executive helped
company exceed asset divestiture and joint venture goals.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
ELAN CORPORATION, plc
By: /s/ William F. Daniel
-----------------------------------
William F. Daniel
Company Secretary
Date: February 17, 2004
Exhibit 99.1
FOR IMMEDIATE RELEASE
Investors: Media:
Emer Reynolds Anita Kawatra
Ph: 353-1-709-4000 Ph: 212-407-5755
800-252-3526 800-252-3526
EXECUTIVE VICE PRESIDENT SEAMUS MULLIGAN LEAVING
ELAN UPON SUCCESSFUL COMPLETION OF RECOVERY PLAN
Elan executive helped company exceed asset divestiture and joint venture goals
Dublin, Ireland, February 16, 2004 -- Elan Corporation, plc today announced that
Seamus C. Mulligan, executive vice president, business and corporate
development, is leaving the company upon the successful completion of its
recovery plan. Mr. Mulligan is leaving to actively pursue other opportunities
within the pharmaceutical industry.
Mr. Mulligan, who joined Elan in 1984, managed the Elan Enterprises business
unit since July 2002, when the company announced a recovery plan to restructure
its businesses, assets and balance sheet. Mr. Mulligan played a pivotal
leadership role in executing this plan, with responsibility for the company's
asset divestitures and joint venture restructurings. The recovery plan resulted
in divestiture proceeds of more than $2 billion, $500 million ahead of the
announced target of $1.5 billion. Elan announced the successful conclusion of
the plan and the end of operations for its Elan Enterprises business unit last
week.
Kelly Martin, Elan President and CEO, commented, "We appreciate Seamus's many
contributions and devotion to Elan, especially in the last 20 months, and wish
him well in his future endeavours."
About Elan
Elan is focused on the discovery, development, manufacturing, sale and marketing
of novel therapeutic products in neurology, severe pain and autoimmune diseases.
Elan (NYSE: ELN) shares trade on the New York, London and Dublin Stock
Exchanges.